X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (76) 76
male (56) 56
female (55) 55
middle aged (53) 53
adult (50) 50
index medicus (37) 37
aged (36) 36
gastroenterology & hepatology (33) 33
hepatitis c, chronic - drug therapy (33) 33
antiviral agents - therapeutic use (30) 30
drug therapy, combination (25) 25
hepatitis c (24) 24
interferon-alpha - therapeutic use (22) 22
ribavirin - therapeutic use (22) 22
treatment outcome (22) 22
hepatitis c virus (20) 20
hepacivirus - genetics (18) 18
interferon (18) 18
ribavirin (17) 17
genotype (16) 16
hepatitis (16) 16
hepatitis c, chronic - virology (16) 16
recombinant proteins (16) 16
gastroenterology and hepatology (15) 15
hepatitis c, chronic - complications (15) 15
polyethylene glycols - therapeutic use (15) 15
ribavirin - administration & dosage (14) 14
adolescent (13) 13
cirrhosis (13) 13
therapy (13) 13
virus-infection (13) 13
antiviral agents - administration & dosage (12) 12
prospective studies (12) 12
sustained virological response (12) 12
antiviral agents - adverse effects (11) 11
hepatitis c - drug therapy (11) 11
infectious diseases (11) 11
interferon-alpha - administration & dosage (11) 11
liver - pathology (11) 11
child (10) 10
fibrosis (10) 10
follow-up studies (10) 10
hepatology (10) 10
infection (10) 10
liver (10) 10
liver diseases (10) 10
plus ribavirin (10) 10
risk factors (10) 10
virology (10) 10
hematology (9) 9
liver cirrhosis - pathology (9) 9
liver cirrhosis - virology (9) 9
settore med/12 - gastroenterologia (9) 9
aged, 80 and over (8) 8
hepacivirus - drug effects (8) 8
hepatitis c, chronic - pathology (8) 8
liver cirrhosis - drug therapy (8) 8
patients (8) 8
recombinant proteins - therapeutic use (8) 8
ribavirin - adverse effects (8) 8
time factors (8) 8
cohort studies (7) 7
drug therapy (7) 7
gastroenterology (7) 7
hcv (7) 7
hepacivirus (7) 7
hepatitis c, chronic - genetics (7) 7
hepatocellular-carcinoma (7) 7
interferon-alpha - adverse effects (7) 7
medicine (7) 7
pegylated interferon (7) 7
polyethylene glycols - administration & dosage (7) 7
viral load (7) 7
viremia (7) 7
biological response modifiers (6) 6
child, preschool (6) 6
chronic disease (6) 6
combination (6) 6
disease (6) 6
follow-up (6) 6
genetic-variation (6) 6
hepatitis-c virus (6) 6
interferons - therapeutic use (6) 6
liver cirrhosis (6) 6
liver cirrhosis - complications (6) 6
liver fibrosis (6) 6
liver-disease (6) 6
multidisciplinary sciences (6) 6
natural-history (6) 6
pharmacology & pharmacy (6) 6
polymorphism, single nucleotide (6) 6
research (6) 6
rna, viral - blood (6) 6
science (6) 6
viruses (6) 6
young adult (6) 6
alanine transaminase - blood (5) 5
antiviral therapy (5) 5
biopsy (5) 5
chronic hepatitis c (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Gastroenterology & Hepatology, ISSN 1759-5045, 09/2010, Volume 7, Issue 9, pp. 485 - 494
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 12/2009, Volume 51, Issue 6, p. 1097
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J,... 
Interferon alpha | Hepatitis C | Biological response modifiers
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2009, Volume 51, Issue 6, pp. 1097 - 1099
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J,... 
Gastroenterology and Hepatology
Journal Article
Gastroenterology, ISSN 0016-5085, 2010, Volume 138, Issue 1, pp. 108 - 115
Background & Aims Ribavirin (RBV) combined with either pegylated interferon (PegIFN) α2a or PegIFNα2b is the standard of care for chronic hepatitis C virus... 
Gastroenterology and Hepatology
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 2276 - 2276
Abstract Abstract 2276 Background: Chronic hepatitis C is the main cause of morbidity and mortality in patients with hemophilia. HCV eradication is the only... 
Journal Article
Gut, ISSN 0017-5749, 05/2010, Volume 59, Issue 5, pp. 638 - 644
Journal Article
Blood, ISSN 0006-4971, 11/2009, Volume 114, Issue 22, pp. 4064 - 4064
Abstract Abstract 4064 Poster Board III-999 Introduction Liver disease is the second cause of death for thalassemia major (TM) patients, mainly due to HCV... 
Journal Article
Journal Article
Nature Reviews Gastroenterology & Hepatology, ISSN 1759-5045, 09/2010, Volume 7, Issue 9, p. 485
Chronic infection with HCV has an estimated prevalence of 1.6-2.0% worldwide and is a major cause of liver-related death. The first attempts to halt the... 
Peginterferon alfa-2b | Dosage and administration | Peginterferon alfa-2a | Research | Hepatitis C | Drug therapy
Journal Article
Journal Article